Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$3.38B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.19B
EBITDA Margin
-15.32%
TTM Avg
-40.28%
3Y Avg
-284.43%
5Y Avg
-231.70%
Market Cap
$3.44B
EBITDA Margin
-21676.57%
TTM Avg
-21676.57%
3Y Avg
-14888.43%
5Y Avg
-11379.97%
Market Cap
$3.48B
EBITDA Margin
-70.74%
TTM Avg
-2343.52%
3Y Avg
-1340.84%
5Y Avg
-951.82%
Market Cap
$3.12B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.31B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | -1.23% | 8.45% | -16.90% | -13.40% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 10.88% | 18.32% | -3.89% | -19.05% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -15.32% | -40.28% | -284.43% | -231.70% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -21676.57% | -21676.57% | -14888.43% | -11379.97% |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -70.74% | -2343.52% | -1340.84% | -951.82% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -359.19% | -174.35% | -417.41% | -1450.57% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.38% | -8.27% | -15.09% | -16.30% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
